Periodontal
Disease Therapeutics Market by Drug Type (Arestin, Atridox, Doxycycline,
Metronidazole, Minocycline, Periochip, and Others), by Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online) - Size, Share, Outlooks,
and Opportunity Analysis 2018 - 2026
Periodontitis is a chronic
bacterial infection caused by microbial plaque often known as gum disease that
is colonized on tooth surface and below the gingival margin. It involves
progressive loss of the alveolar bone, which is a thickened ridge of bone that
contains tooth socket over the bones that holds teeth. According to National
Institutes of Health 2017, around 20-15% of global population is estimated to suffer
from severe periodontitis in comparison to 5-10% in 2004, which is propelling
demand for its diagnosis and treatment worldwide in the medical industry.
In periodontitis, gums are pulled
away from teeth and form spaces (pockets), which are prone to get infected. If
such infection is untreated, it can lead to increase periodontal pocket length
and bleeding on probe, in turn leading to the alveolar bone loss and teeth
loss. In order to complement a non-surgical therapy in periodontitis multiple
antimicrobial options are available, such as metronidazole, chlorhexidine,
minocycline, doxycycline, tetracycline, which can be locally delivered to
mucosa. These drugs are used to inhibit periodontopathogenic microorganism as
well as modulate the inflammatory response of tissues.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2022
Periodontal Disease Therapeutics
Market Drivers
Oral care and dental hygiene are
one of the major concerns worldwide. High prevalence of periodontal disease is
propelling demand for oral treatment. Periodontal disease is a result of various
risk factors, such as aging, smoking, poor oral hygiene, heredity, stress, and
other medical conditions.
Periodontal disease are majorly
observed in adults. According to the Centre for Disease Control and Prevention
(CDC), in 2018, the prevalence of periodontitis has been estimated to be over
50% in U.S. adults aged 30 years and older i.e. 64.7 million Americans. Among
those adults, 8.7% showed mild disease, 30% demonstrated moderate disease, 8.5%
had severe chronic periodontitis. Disease prevalence increases with age, with
70% adults, who are 65 years and above, suffering from periodontitis. There are
many environmental risk factors that are associated with inflammatory
responses, which include smoking, diabetes mellitus, and poor health habits driving
the chronic inflammatory response in periodontitis, and are beneficial for the
periodontitis disease therapeutic market.
Also, advancements in treatment
by using novel drugs is expected to fuel the periodontal disease therapeutics
market growth. For instance, in January 2017, ST266 by Noveome Biotherapeutics,
Inc., is an expected candidate for disease treatment, which is currently in
phase I clinical trials. ST266, is used to treat patients with moderate to
severe periodontitis. It provide essential tools at critical stages of the
healing process to restore homeostasis within the periodontal
microenvironment.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/periodontal-disease-therapeutics-market-2022
Local antibiotics for the
treatment of periodontal disease to present more growth opportunities in the
periodontal disease therapeutics market. Increasing preference for controlled
local drug delivery approaches over systemic drug delivery due to better
therapeutic outcomes by achieving factors such as site specific delivery, low
dose requirement, reduces side effects favors the growth of local antibiotics.
Furthermore, it provide safe and effective mode of treatment and is expected to
lead the market in the next few years due to various advantages. Systemic
antibiotics is expected to hold dominance in global market due to factors such
as product affordability, availability, and high market penetration. Growing
number of preventive care for dental and gum problems and poor reimbursement
policies in many economies are hindering the growth of periodontal disease
therapeutic market.
Periodontal Disease Therapeutics
Market Regional Analysis
Based on geography, North America
dominated the periodontal disease therapeutics market due to high awareness of
periodontal disease. High prevalence of periodontal disease due to desk bound
or seated lifestyle, efficient reimbursements, and drug abuse. Also, increased
healthcare spending has contributed to growth of market. For instance, in the
U.S., according to the Centers for Medicare and Medicaid Services (CMS)
spending for dental services increased by 4.6% in 2016, to US $124.4 Bn, a
slight acceleration from 4.4% in growth in 2015. Furthermore, Asia Pacific is
expected as an emerging lucrative market for periodontal therapeutics market
due to large patient pool, growing healthcare infrastructure, and expenditure.
Also, investments into research and development for more effective therapies by
prominent players in the region drives the periodontal disease therapeutics
market.
Periodontal Disease Therapeutics
Market Competitor Analysis
Key players in operating in the
periodontal disease therapeutic market include DenMat Holdings LLC., 3M,
Valeant Pharmaceuticals International, Inc., Galderma S.A., Dexcel Pharma Ltd.,
Kaken Pharmaceutical Co., Ltd., and OraPharma Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2022
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment